DOCSLIB.ORG

HPV and Adolescent Vaccine Toolkit: Clinician Guide Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HPV and Adolescent Vaccine Toolkit: Clinician Guide Contents HPV and Adolescent Vaccine Toolkit: Clinician Guide CONTENTS I. 2018 IMMUNIZATION SCHEDULES & SCREENING RESOURCES Recommended & Catch-up Immunization Schedule (Birth-18 Years) Lists the ages or age range each vaccine is recommended. Schedules are updated annually. Please visit https://www.cdc.gov/vaccines/schedules/ for the most up-to-date schedules. Clinician FAQ: CDC Recommendations for HPV Vaccine 2-Dose Schedules Helps explain the new HPV vaccine recommendation for adolescents (2 doses recommended for adolescents starting the series before their 15th birthday; 3 doses recommended for adolescents starting the series after their 15th birthday) and provides tips for talking to parents about the change. HPV 2-Dose Decision Tree Follow the decision tree chart to determine whether your patient needs two or three doses of HPV vaccine. II. ADDRESSING VACCINE HESITANCY Talking to Parents About the HPV Vaccine A collection of questions parents may have surrounding the HPV vaccine and responses healthcare providers can use to address the concerns. Let’s Talk Vaccines: A Guide to Conversations About Immunizations Parents ask tough questions! Use this resource from Northwest Vax to provide a strong recommendation using the Ask. Acknowledge. Advise model. III. BEST PRACTICES AND STRATEGIES FOR IMPROVING IMMUNIZATION COVERAGE RATES Strategies for Improving Adolescent Immunization Coverage Rates Use the strategies in this AAP resource to help your practice improve adolescent immunization coverage rates among your patients. Documenting Parental Refusal to Have Their Children Vaccinated Provides tips from the AAP on ways to communicate with and educate parents who refuse immunizations. Includes a template for use by health care providers to document refusals. CONTENTS CONTINUED Adolescent Vaccine Information for Healthcare Professionals Provides information on the four routinely recommended adolescent vaccines: Tdap, HPV, Influenza and Meningococcal. Top 10 List for HPV #VaxSuccess Lists 10 strategies clinicians can use to attain and maintain high HPV vaccination rates in their clinics. Using Standing Orders for Administering Vaccines: What You Should Know Describes standing orders and promotes its use in the delivery of immunization services to patients to increase vaccination coverage rates. IV. DATA & STATISTICS HPV Cancer & Prevention Profile—Texas Provides an overview of HPV vaccination rates compared to that of Tdap and Meningococcal vaccines in the U.S and Texas. Also, provides a comparison of the incidence of HPV-associated cancers in the U.S. and Texas and the percentage of cancers linked to HPV. Average Annual Number of New Cancers Probably Caused by HPV: AAP An AAP graph detailing the average annual number of new cases probably caused by HPV in women and men. Incidence of Diseases Covered in Adolescent Vaccine Series: AAP An AAP graph detailing the annual incidence of diseases that can be prevented with the adolescent vaccine series. Deaths from Diseases Covered in Adolescent Vaccine Series: AAP An AAP graph detailing the estimated annual deaths from diseases that can be prevented with the adolescent vaccine series. CONTENTS CONTINUED V. QUALITY IMPROVEMENT TOOLS Plan, Do, Study, Act (PDSA) Model for Improvement Resource An AAP resource providing quality improvement strategies guiding clinicians on the planning stages of identifying a problem, implementing the solution and measuring outcomes. Huddle Your Way to Better Immunization Rates An AAP resource providing ideas on how to incorporate immunizations into your practice’s daily huddles. VI. OTHER RESOURCES Promotional Materials for Adolescent Vaccines Flyers included in both English and Spanish that can be displayed in your practice promoting all adolescent vaccines. Visit www.cdc.gov/vaccines/ed/patient-ed.htm for additional promotional materials. Vaccine Information Statements and Important Information about VISs VISs are information sheets produced by the CDC, that explain both the benefits and risks of a vaccine to vaccine recipients. Federal law requires that healthcare staff provide a VIS to a patient, parent, or legal representative before each dose of certain vaccines. Enclosed are the most current VISs for the recommended adolescent vaccines in English, Spanish and Vietnamese. Visit www.cdc.gov/vaccines/hcp/vis/current-vis.html for a link to all current VISs. Video Resources Provides links to videos detailing personal stories of individuals and families affected by vaccine-preventable diseases. Download a QR Scanner App on your phone for easy access to videos! I I 2018 Immunization Schedules & Screening Resources . Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2018 The table below shows vaccine acronyms, and brand names for vaccines routinely recommend- ed for children and adolescents. The use of trade names in this immunization schedule is for • Consult relevant ACIP statements for detailed recommendations identification purposes only and does not imply endorsement by the ACIP or CDC. (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Vaccine type Abbreviation Brand(s) • When a vaccine is not administered at the recommended age, Diphtheria, tetanus, and acellular pertussis vaccine DTaP Daptacel administer at a subsequent visit. Infanrix Diphtheria, tetanus vaccine DT No Trade Name • Use combination vaccines instead of separate injections when Haemophilus influenzae type B vaccine Hib (PRP-T) ActHIB appropriate. Hiberix Hib (PRP-OMP) PedvaxHIB • Report clinically significant adverse events to the Vaccine Adverse Hepatitis A vaccine HepA Havrix Event Reporting System (VAERS) online (www.vaers.hhs.gov) or by Vaqta Hepatitis B vaccine HepB Engerix-B telephone (800-822-7967). Recombivax HB • Report suspected cases of reportable vaccine-preventable diseases Human papillomavirus vaccine HPV Gardasil 9 to your state or local health department. Influenza vaccine (inactivated) IIV Multiple • For information about precautions and contraindications, see www. Measles, mumps, and rubella vaccine MMR M-M-R II Meningococcal serogroups A, C, W, Y vaccine MenACWY-D Menactra cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html. MenACWY-CRM Menveo Meningococcal serogroup B vaccine MenB-4C Bexsero MenB-FHbp Trumenba Approved by the Pneumococcal 13-valent conjugate vaccine PCV13 Prevnar 13 Pneumococcal 23-valent polysaccharide vaccine PPSV23 Pneumovax Advisory Committee on Immunization Practices Poliovirus vaccine (inactivated) IPV IPOL (www.cdc.gov/vaccines/acip) Rotavirus vaccines RV1 Rotarix RV5 RotaTeq American Academy of Pediatrics Tetanus, diphtheria, and acellular pertussis vaccine Tdap Adacel (www.aap.org) Boostrix Tetanus and diphtheria vaccine Td Tenivac No Trade Name American Academy of Family Physicians Varicella vaccine VAR Varivax (www.aafp.org) Combination Vaccines American College of Obstetricians and Gynecologists DTaP, hepatitis B and inactivated poliovirus vaccine DTaP-HepB-IPV Pediarix DTaP, inactivated poliovirus and Haemophilus influenzae DTaP-IPV/Hib Pentacel (www.acog.org) type B vaccine This schedule includes recommendations in effect as of January 1, 2018. DTaP and inactivated poliovirus vaccine DTaP-IPV Kinrix Quadracel Measles, mumps, rubella, and varicella vaccines MMRV ProQuad U.S. Department of Health and Human Services Centers for Disease Control and Prevention Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2018. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray. 19-23 Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos 2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13-15 yrs 16 yrs 17-18 yrs mos Hepatitis B1 (HepB) 1st dose 2nd dose 3rd dose Rotavirus2 (RV) RV1 (2-dose See 1st dose 2nd dose series); RV5 (3-dose series) footnote 2 Diphtheria, tetanus, & acellular 1st dose 2nd dose 3rd dose 4th dose 5th dose pertussis3 (DTaP: <7 yrs) Haemophilus influenzae type b4 rd th 1st dose 2nd dose See 3 or 4 dose, (Hib) footnote 4 See footnote 4 Pneumococcal conjugate5 1st dose 2nd dose 3rd dose 4th dose (PCV13) Inactivated poliovirus6 1st dose 2nd dose 3rd dose 4th dose (IPV: <18 yrs) 7 Annual vaccination (IIV) Influenza (IIV) Annual vaccination (IIV) 1 or 2 doses 1 dose only Measles, mumps, rubella8 (MMR) See footnote 8 1st dose 2nd dose Varicella9 (VAR) 1st dose 2nd dose Hepatitis A10 (HepA) 2-dose series, See footnote 10 Meningococcal11 (MenACWY-D See footnote 11 1st dose 2nd dose >9 mos; MenACWY-CRM ≥2 mos) Tetanus, diphtheria, & acellular Tdap pertussis13 (Tdap: >7 yrs) 14 See footnote Human papillomavirus (HPV) 14 See footnote 12 Meningococcal B12 Pneumococcal polysaccharide5 See footnote 5 (PPSV23) Range of recommended Range of recommended ages Range of recommended ages Range of recommended ages for non-high-risk No recommendation ages for all children for catch-up immunization for certain high-risk groups groups that may receive vaccine, subject to individual clinical decision making NOTE: The above recommendations must be read along with the footnotes of this schedule. FIGURE 2. Catch-up immunization schedule for persons aged 4 months–18
Load more

Recommended publications
  • Gavi's Vaccine Investment Strategy
    Gavi’s Vaccine Investment Strategy Deepali Patel THIRD WHO CONSULTATION ON GLOBAL ACTION PLAN FOR INFLUENZA VACCINES (GAP III) Geneva, Switzerland, 15-16 November 2016 www.gavi.org Vaccine Investment Strategy (VIS) Evidence-based approach to identifying new vaccine priorities for Gavi support Strategic investment Conducted every 5 years decision-making (rather than first-come- first-serve) Transparent methodology Consultations and Predictability of Gavi independent expert advice programmes for long- term planning by Analytical review of governments, industry evidence and modelling and donors 2 VIS is aligned with Gavi’s strategic cycle and replenishment 2011-2015 Strategic 2016-2020 Strategic 2021-2025 period period 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 RTS,S pilot funding decision VIS #1 VIS #2 VIS #3 MenA, YF mass campaigns, JE, HPV Cholera stockpile, Mid 2017 : vaccine ‘long list’ Rubella, Rabies/cholera studies, Oct 2017 : methodology Typhoid Malaria – deferred Jun 2018 : vaccine shortlist conjugate Dec 2018 : investment decisions 3 VIS process Develop Collect data Develop in-depth methodology and Apply decision investment decision framework for cases for framework with comparative shortlisted evaluation analysis vaccines criteria Phase I Narrow long list Phase II Recommend for Identify long list to higher priority Gavi Board of vaccines vaccines approval of selected vaccines Stakeholder consultations and independent expert review 4 Evaluation criteria (VIS #2 – 2013) Additional Health Implementation
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Pneumococcal Vaccine
    Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal Disease • 2nd most common cause of vaccine preventable death in the US • Major Syndromes – Pneumonia – Bacteremia – Meningitis Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2010 (ORIG) Vaccine Target • Polysaccharide capsule allows bacteria to resist phagocytosis • Antibodies to capsule facilitate phagocytosis • >90 different pneumococcal capsular serotypes • Vaccines contain most common serotypes causing disease Pneumococcal Vaccines Pneumococcal Vaccines • Pneumococcal polysaccharide vaccine (PPSV23; Pneumovax) – Contains capsular polysaccharides – 23 most commonly infecting serotypes • Cause 60% of all pneumococcal infections in adults – Not recommended for children <2 due to poor immunogenicity of polysaccharides Pneumococcal Vaccines • Pneumococcal conjugate vaccine (PCV13, Prevnar) – Polysaccharides linked to nontoxic protein • higher antigenicity – Stimulates mucosal antibody • Eliminates nasal carriage in young children • Herd effect in adults – Reduction in PCV7 serotype disease >90% Prevnar 13 • 2000 - PCV7 approved for infants toddlers • 2010 - PCV13 recommended for infants and toddlers • 2012 – ACIP recommended PCV13 for high- risk adults • 2014 – recommended for adults >65 • 2018 – ACIP will revisit PCV13 use in adults – Childhood vaccines may eliminate
    [Show full text]
  • Even Partial COVID-19 Vaccination Protects Nursing Home Residents
    News & Analysis News From the Centers for Disease Control and Prevention Even Partial COVID-19 Vaccination lence of underlying medical conditions,” the Protects Nursing Home Residents authors wrote. A CDC analysis has shown that a single dose Waning COVID-19 cases as more resi- of the Pfizer-BioNTech COVID-19 vaccine dents and staff received second vaccina- protected medically vulnerable nursing tions made it impossible to assess vaccine ef- home residents as well as it did general adult fectiveness after 2 doses. Evidence from populations that were evaluated in other ef- previous studies demonstrated greater pro- ficacy and effectiveness studies. tection among older adults after a second The analysis helps fill a data gap about dose, suggesting that completing the 2-dose vaccine effectiveness in this high-risk regimen may be particularly important to group—generally older, frail adults with un- protect long-term care facility residents, the derlying health conditions—who were left authors suggested. out of COVID-19 vaccine trials. Excluding older adults from the trials raised questions Vaccine Dramatically Reduces HPV about how well nursing home residents Infection Among Young Women would respond to vaccination. Widespread vaccination of young women By analyzing the Pfizer-BioNTech vac- against human papillomavirus (HPV) has led cine’sperformanceduringalateJanuaryout- to a greater than 80% reduction in infec- the 4 HPV strains most likely to cause dis- break at 2 Connecticut skilled nursing facili- tions with the 4 strains most often associ- ease. Newer versions that protect against 9 ties, investigators from the CDC and the ated with disease, according to a CDC study.
    [Show full text]
  • Summary Guide to Tetanus Prophylaxis in Routine Wound Management
    Summary Guide to Tetanus Prophylaxis in Routine Wound Management ASSESS WOUND A clean, minor wound All other wounds (contaminated with dirt, feces, saliva, soil; puncture wounds; avulsions; wounds resulting from flying or crushing objects, animal bites, burns, frostbite) Has patient completed a primary Has patient completed a primary tetanus diphtheria series?1, 7 tetanus diphtheria series?1, 7 No/Unknown Yes No/Unknown Yes Administer vaccine today.2,3,4 Was the most recent Administer vaccine and Was the most Instruct patient to complete dose within the past tetanus immune gobulin recent dose within series per age-appropriate 10 years? (TIG) now.2,4,5,6,7 the past 5 years?7 vaccine schedule. No Yes No Yes Vaccine not needed today. Vaccine not needed today. Administer vaccine today.2,4 2,4 Patient should receive next Administer vaccine today. Patient should receive next Patient should receive next dose Patient should receive next dose dose at 10-year interval after dose at 10-year interval after per age-appropriate schedule. per age-appropriate schedule. last dose. last dose. 1 A primary series consists of a minimum of 3 doses of tetanus- and diphtheria- 4 Tdap* is preferred for persons 11 through 64 years of age if using Adacel* or 10 years of containing vaccine (DTaP/DTP/Tdap/DT/Td). age and older if using Boostrix* who have never received Tdap. Td is preferred to tetanus 2 Age-appropriate vaccine: toxoid (TT) for persons 7 through 9 years, 65 years and older, or who have received a • DTaP for infants and children 6 weeks up to 7 years of age (or DT pediatric if Tdap previously.
    [Show full text]
  • HPV – Facts About the Virus, the Vaccine and What This Means For
    The WHO Regional The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters each with its own programme geared to the particular health conditions of the countries it serves. Member States Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Cyprus Czechia HPV – facts about the virus, Denmark Estonia Finland France the vaccine and what this Georgia Germany Greece means for you Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Answers to common questions Latvia Lithuania asked by adolescents and Luxembourg Malta young adults Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan The former Yugoslav Republic of Macedonia Turkey Turkmenistan Ukraine United Kingdom UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Uzbekistan Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01 E-mail: [email protected] Q&A: Answers to common questions asked by adolescents and young adults HPV and vaccination HPV stands for human papillomavirus. There are over What is HPV and why should I be vaccinated 200 known types of the virus, 30 of which are transmitted against it? through sexual activity. HPV is the most common sexually transmitted infection in the world. Almost 80% of sexually active people will get infected with one or more HPV types in their lifetime. HPV infection can lead to several types of cancer and genital warts. Cervical cancer is the most common type of cancer caused by HPV, and it is the fourth most common cancer in women worldwide.
    [Show full text]
  • Package Insert
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------------- CONTRAINDICATIONS ------------------------------------- These highlights do not include all the information needed to use ® • History of severe allergic reactions (e.g., anaphylaxis) to egg proteins, or any FLUVIRIN (Influenza Virus Vaccine) safely and effectively. See full ® ® component of FLUVIRIN , or life-threatening reactions to previous influenza prescribing information for FLUVIRIN . vaccinations. (4.1, 11) FLUVIRIN® (Influenza Virus Vaccine) Suspension for Intramuscular Injection ---------------------- WARNINGS AND PRECAUTIONS ------------------------------ 2017-2018 Formula • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior Initial US Approval: 1988 influenza vaccine, the decision to give FLUVIRIN® should be based on -------------------------- INDICATIONS AND USAGE ---------------------------------- careful consideration of the potential benefits and risks. (5.1) ® • FLUVIRIN is an inactivated influenza virus vaccine indicated for active • Immunocompromised persons may have a reduced immune response to immunization of persons 4 years of age and older against influenza disease FLUVIRIN®. (5.2) caused by influenza virus subtypes A and type B contained in the vaccine (1). • The tip caps of the FLUVIRIN® prefilled syringes may contain natural rubber • FLUVIRIN® is not indicated for children less than 4 years of age because latex which may cause allergic reactions in latex sensitive individuals. there is evidence of diminished immune response
    [Show full text]
  • YF-VAX® Rx Only AHFS Category
    YF-VAX® Rx Only Laboratory Personnel AHFS Category: 80:12 Laboratory personnel who handle virulent yellow fever virus or concentrated preparations Rx only of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect Yellow Fever Vaccine contact or by aerosols. (14) DESCRIPTION CONTRAINDICATIONS ® Hypersensitivity YF-VAX , Yellow Fever Vaccine, for subcutaneous use, is prepared by culturing the YF-VAX is contraindicated in anyone with a history of acute hypersensitivity reaction to any 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken component of the vaccine. (See DESCRIPTION section.) Because the yellow fever virus embryos. The vaccine contains sorbitol and gelatin as a stabilizer, is lyophilized, and is used in the production of this vaccine is propagated in chicken embryos, do not administer hermetically sealed under nitrogen. No preservative is added. Each vial of vaccine is YF-VAX to anyone with a history of acute hypersensitivity to eggs or egg products due to supplied with a separate vial of sterile diluent, which contains Sodium Chloride Injection a risk of anaphylaxis. Less severe or localized manifestations of allergy to eggs or to USP – without a preservative. YF-VAX is formulated to contain not less than 4.74 log10 feathers are not contraindications to vaccine administration and do not usually warrant plaque forming units (PFU) per 0.5 mL dose throughout the life of the product. Before vaccine skin testing. (See PRECAUTIONS section, Testing for Hypersensitivity Re- reconstitution, YF-VAX is a pinkish color. After reconstitution, YF-VAX is a slight pink-brown actions subsection.) Generally, persons who are able to eat eggs or egg products may suspension.
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]
  • Meningococcal Vaccine Q & a for Healthcare Providers
    Meningococcal Vaccine Q & A for Healthcare Providers School meningococcal vaccine requirements Q1: When did the school meningococcal vaccine requirement take effect? A1: The meningococcal vaccine school requirement took effect on September 1, 2016. Q2: For what grades is meningococcal vaccine required? A2: Meningococcal vaccine is currently required for students entering or attending grades 7 through 12 in public, private and parochial New York State (NYS) schools. Q3: How many doses of meningococcal vaccine are required for grades 7 through 11? A3: One dose of meningococcal conjugate vaccine (MenACWY; sometimes abbreviated as MCV4; brand names Menactra or Menveo) is required for entry into grades 7 through 11. Q4: How many doses of meningococcal vaccine are required for grade 12? A4: A total of two doses of MenACWY vaccine, administered a minimum of 8 weeks apart, are required for entry into grade 12. The second dose must be administered no sooner than 16 years of age. However, if the first dose of MenACWY vaccine was received at 16 years of age or older, then a second dose will not be required. The NYS school immunization requirements allow for a grace period of up to 4 days before the 16th birthday for receipt of the dose. A dose of vaccine received 5 or more days before the 16th birthday will not meet the 12th grade meningococcal vaccine requirement. Q5: Is serogroup B meningococcal vaccine (MenB vaccine) required for grade 12? A5: No, MenB vaccine is not required for school attendance in NYS. In addition, doses of MenB vaccine will not meet the NYS MenACWY vaccine requirement.
    [Show full text]
  • Supplemental Information and Guidance for Vaccination Providers Regarding Use of 9-Valent HPV Vaccine
    Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV A 9-valent human papillomavirus (HPV) vaccine (9vHPV, Gardasil 9, Merck & Co.) was licensed for use in females and males in December 2014.1,2,3,4 The 9vHPV was the third HPV vaccine licensed in the United States by the Food and Drug Administration (FDA); the other vaccines are bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline), licensed for use in females, and quadrivalent HPV vaccine (4vHPV, Gardasil, Merck & Co.), licensed for use in females and males.5 In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males.6 After the end of 2016, only 9vHPV will be distributed in the United States. In October 2016, ACIP updated HPV vaccination recommendations regarding dosing schedules.7 CDC now recommends two doses of HPV vaccine (0, 6–12 month schedule) for persons starting the vaccination series before the 15th birthday. Three doses of HPV vaccine (0, 1–2, 6 month schedule) continue to be recommended for persons starting the vaccination series on or after the 15th birthday and for persons with certain immunocompromising conditions. Guidance is needed for persons who started the series with 2vHPV or 4vHPV and may be completing the series with 9vHPV. The information below summarizes some of the recommendations included in ACIP Policy Notes and provides additional guidance.5-7 Information about the vaccines What are some of the similarities and differences between the three HPV vaccines? y Each of the three HPV vaccines is a noninfectious, virus-like particle (VLP) vaccine.
    [Show full text]